TSC1 and neoplasm: Targeting key components of tumor suppressors, such as phosphatase and tensin homolog (PTEN), tuberous sclerosis 1/2 (TSC1/2), neurofibromin 1/2 (NF1/2), or oncogenic mutations in KRAS, PIK3CA, or AKT, may represent an effective treatment to kill acute myeloid leukemia and leukemia stem cells, according to growing evidence (Grabiner et al. 2014).